IDEXX Laboratories, Inc. (IDXX) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
IDXX Revenue Growth
Revenue Breakdown (FY 2025)
IDXX's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
IDXX Revenue Analysis (2014–2025)
As of May 8, 2026, IDEXX Laboratories, Inc. (IDXX) generated trailing twelve-month (TTM) revenue of $4.45 billion, reflecting strong growth of +14.3% year-over-year. The most recent quarter (Q1 2026) recorded $1.14 billion in revenue, up 4.6% sequentially.
Looking at the longer-term picture, IDXX's 5-year compound annual growth rate (CAGR) stands at +9.7%, indicating steady revenue expansion. The company achieved its highest annual revenue of $4.30 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows IDXX's business is primarily driven by Product (59%), and Service (41%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ZTS (+2.4% YoY), HSIC (+4.0% YoY), and ELAN (+10.5% YoY), IDXX has underperformed the peer group in terms of revenue growth. Compare IDXX vs ZTS →
IDXX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| IDXXCurrent | $4.4B | +14.3% | +9.7% | 31.6% | |
 ZTS | $9.5B | +2.4% | +7.2% | 38.0% | |
 HSIC | $13.2B | +4.0% | +5.4% | 5.7% | |
 ELAN | $4.7B | +10.5% | +7.6% | 5.3% | |
 ANIP | $883M | +43.8% | +33.5% | 12.6% | |
 NEOG | $895M | -3.7% | +16.4% | 1.1% |
IDXX Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $4.30B | +10.4% | $2.66B | 61.8% | $1.36B | 31.6% |
| 2024 | $3.90B | +6.5% | $2.38B | 61.0% | $1.13B | 29.0% |
| 2023 | $3.66B | +8.7% | $2.19B | 59.8% | $1.10B | 30.0% |
| 2022 | $3.37B | +4.7% | $2.00B | 59.5% | $898.8M | 26.7% |
| 2021 | $3.22B | +18.8% | $1.89B | 58.8% | $932.0M | 29.0% |
| 2020 | $2.71B | +12.5% | $1.57B | 58.0% | $694.5M | 25.7% |
| 2019 | $2.41B | +8.8% | $1.37B | 56.7% | $552.8M | 23.0% |
| 2018 | $2.21B | +12.4% | $1.24B | 56.1% | $491.3M | 22.2% |
| 2017 | $1.97B | +10.9% | $1.10B | 55.7% | $413.0M | 21.0% |
| 2016 | $1.78B | +10.8% | $975.4M | 54.9% | $350.2M | 19.7% |
Full IDXX Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See IDXX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IDXX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare IDXX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonIDXX — Frequently Asked Questions
Quick answers to the most common questions about buying IDXX stock.
Is IDXX's revenue growth accelerating or slowing?
IDXX maintains +14.3% revenue growth, in line with its 5-year CAGR of +9.7%. TTM revenue stands at $4.4B. Growth rate remains consistent with historical average.
What is IDXX's long-term revenue growth rate?
IDEXX Laboratories, Inc.'s 5-year revenue CAGR of +9.7% reflects the sustained expansion pattern. Current YoY growth of +14.3% is near this long-term average.
How is IDXX's revenue distributed by segment?
IDXX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.